Name: Cellular Therapies: Revolutionizing Cancer Therapy, Part 3: CTL019 in Relapsed Refractory Pediatric Acute Lymphoblastic Leukemia
Uploaded: 2016-04-08T00:00:00+00:00
Description: In this video, Carl June, MD, reflects on the case of Emily Whitehead, the first pediatric patient treated with CAR T cell therapy for pediatric relapsed, refractory ALL --and her four years in complete remission.

In this third of four videos on the topic of cellular therapies for the hematologic malignancies, Carl H June, MD, describes the case of Emily Whitehead, the first pediatric patient treated with CAR T cell therapy for resistant, refractory acute lymphoblastic leukemia (ALL). Emily is now in her fourth year of complete remission. Dr. June also discusses the ELIANA study now ongoing in pediatric patients with relapsed and refractory B-cell ALL.

To view other parts of this program:

Part 1: Adoptive Cell Therapy - An Introduction

Part 2: CTL019 Therapy in Chronic Lymphocytic Leukemia

Part 4: Adoptive Cell Therapy - Lessons Learned, Issues and the Future